New breakthrough could help treat muscular dystrophy

By Raquel Maurier
U of A medical researcher Toshifumi Yokota used a new drug cocktail to lessen the severity of Duchenne muscular dystrophy symptoms in lab models.

A researcher in the Faculty of Medicine & Dentistry at the University of Alberta improved Duchenne muscular dystrophy symptoms in non-human lab models, using a new drug cocktail. The drug combination targets the “hot spot” of the gene mutation, making the condition less severe.

Toshifumi Yokota, the study’s principal investigator, published his findings Aug. 6 in the peer-reviewed journal, Proceedings of the National Academy of Sciences. He is a researcher in the Department of Medical Genetics and holds two research chairs: The Friends of Garrett Cumming Research Chair, Canada; and the H.M. Toupin Neurological Science Chair.

Yokota has worked on this research for more than five years. He is now using the same on human cells with Duchenne muscular dystrophy and hopes to see similar results.

Duchenne muscular dystrophy, one of the most common genetic disorders, is caused by a lack of dystrophin, a muscle-supporting protein. In the lab, the drug cocktail improved normal functioning of the mutated gene that triggers the condition. The therapy allowed the lab models to produce 10 per cent to 15 per cent normal levels of dystrophin.

“With this drug cocktail, we were able to target the hot-spot mutated parts of the gene,” said Yokota. “The results were very good—better than we expected. The Duchenne muscular dystrophy condition was less severe.”

Yokota noted that about half of those living with Duchenne could potentially benefit from the drug cocktail, once further testing is conducted and clinical trials are completed.

He worked with colleagues in the United States and Japan on the findings.

Related Stories

Researchers review muscular dystrophy therapies

Jun 22, 2012

Leading muscular dystrophy researcher Dean Burkin, of the University of Nevada School of Medicine summarizes the impact of a new protein therapeutic, MG53, for the treatment of Duchenne muscular dystrophy ...

Recommended for you

Gamers helping in Ebola research

10 hours ago

Months before the recent Ebola outbreak erupted in Western Africa, killing more than a thousand people, scientists at the University of Washington's Institute for Protein Design were looking for a way to stop the deadly virus.

Carcinogenic role of a protein in liver decoded

12 hours ago

The human protein EGFR controls cell growth. It has mutated in case of many cancer cells or exists in excessive numbers. For this reason it serves as a point of attack for target-oriented therapies. A study ...

A new way to diagnose malaria, using magnetic fields

Aug 31, 2014

Over the past several decades, malaria diagnosis has changed very little. After taking a blood sample from a patient, a technician smears the blood across a glass slide, stains it with a special dye, and ...

User comments